TCS
IOVA icon

Texas Children's’s Iovance Biotherapeutics IOVA Stock Holding History

Texas Children's’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-64,348
Closed -$612K – 10
2019
Q1 		$612K Buy
+64,348
New +$625K 0.74% 22

Other funds holding IOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Texas Children's's IOVA Position: Q2 2019 in Review

Texas Children's sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 64,348 shares — an estimated $612K sold.

Texas Children's first reported a position in IOVA in Q1 2019 and held it in 1 quarter. The position peaked at $612K in Q1 2019. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

  • Texas Children's reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Texas Children's sold 64,348 Iovance Biotherapeutics shares in Q2 2019, an estimated $612K.
  • Texas Children's first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 1 quarter.
  • Texas Children's's Iovance Biotherapeutics position peaked at $612K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on Texas Children's's 13F filing for Q2 2019, filed 13 Aug 2019.